We’re sorry to announce that our scheduled plenary speaker Joseph Samitier will no longer be able to present at our upcoming event. We truly appreciate your understanding.
Stay tuned for updates, and we look forward to sharing more with you in the coming days.
Plenary Speakers

Professor Monika Stoll
Vice-Rector for Research at the University of Münster
Professor at the University of Münster
Monika Stoll is Vice-Rector for Research at the University of Muenster and Professor of Genetic Epidemiology and Statistical Genetics. Monika Stoll is engaged in research in complex genetics and genetic epidemiology particularly relating to cardiovascular diseases and inflammation. Current research projects address the genetic and genomic basis of arrhythmogenic diseases and heart failure. Her research group is running a core facility for genomics which supports high-density arrays and next-generation sequencing applications and a (bio)informatics infrastructure for management and analysis of large data sets.
Learn more about our speaker at: https://www.carimmaastricht.nl/research/divisions/division_blood/blood_coagulation_venous_thrombosis_bleeding/people/monika_stoll

Doctor Kristof Vercruysse
Chief Executive Officer at TargED Biopharmaceuticals
Kristof Vercruysse has over 20 years of experience in bringing biopharmaceutical compounds from preclinical proof of concept towards market authorization. He holds a Masters in Biomedical Science from Vrije Universiteit Brussel. Kristof gained hands-on experience with the development of Caplacizumab for the treatment of thrombotic thrombocytopenic purpura during his time at Ablynx from 2007 to 2013. Subsequently, Kristof joined Sourcia, a full-service boutique contract research organization that delivers tailor-made clinical drug development for biotech companies, where he developed expertise in the development of biopharmaceuticals and gained valuable insights into the clinical trial process. Currently, Kristof holds the position of Chief Executive Officer at TargED Biopharmaceuticals, a biotechnology company that develops first-in-class biological drugs to improve the treatment of thrombosis.
Learn more about our speaker at: https://targedbiopharmaceuticals.com/employee/kristof-vercruysse/
Keynote Speakers

Professor Rune Matthiensen
Rune Matthiesen leads the computational and experimental biology (CEB) group at NOVA Medical School (NMS), where he focuses on unraveling the mechanisms of drug resistance in cancer through large-scale biological experiments using model systems, followed by biomarker validation in clinical samples. He has extensive experience in large-scale clinical proteomics based on LC-MS, in combination with machine learning and epidemiological computational methodologies. In addition to being responsible for multiple courses and co-responsible for a master's program, he has been Principal Investigator on 15 research projects focusing on clinical proteomics and data integration with clinical samples. Currently, Dr. Matthiesen plays a pivotal role as the coordinator of the prestigious EU project, EVCA - Centre for Excellence in Diagnostic and Advanced Therapeutics based on Extracellular Vesicles (Horizon2020 GA n° 101079264, EVCA).
Learn more about our speaker at: https://www.cienciavitae.pt/BB1A-A606-EE77